If sale figures for the last available data is an indication, GSK has maintaining the rising trend. With BV of 502 (again rising) and dividend of Rs.55/- with face value of Rs.10/- it is enjoying far better price to earning when in comparison to other players. A debt free company it potentially a high efficiency profit generating level currently. One should park some available fund into this for med to long term. More so, when it well serves the purpose a defensive stock in not very good market conditions - besides providing appreciation in price.